Merck and Moderna reported positive Phase III results from INTerpath-001 for intismeran (mRNA-4157/V940), their bespoke AI-designed mRNA therapeutic, when combined with pembrolizumab (Keytruda) in Stage IIB–IV cutaneous melanoma. The program showed improved outcomes versus pembrolizumab alone, marking a rare late-stage success for patient-specific mRNA immunotherapy. The study enrolled more than 1,100 participants, with dosing configured alongside safety rules to stop treatment for unacceptable toxicity. While full detailed endpoints were not provided in the excerpt, the reported signal positions the combination as a potentially regulatory-relevant proof point for customization at scale. Beyond melanoma, the result sets a benchmark for how AI-generated biologics may move through confirmatory trials and regulatory review—especially for therapies that tailor antigenic payloads to individual patients.